Literature DB >> 19265564

The saga of schistosome migration and attrition.

R A Wilson1.   

Abstract

Schistosomes infect the mammalian host by direct penetration of the skin and must then undergo a protracted migration to the site of parasitization, for Schistosoma mansoni the hepatic portal vasculature. This article reviews the work published roughly between 1976 and 1986 that clarified our understanding of the process in the laboratory mouse. A combination of histopathology, larval injection experiments and autoradiographic tracking revealed that migration involved one to several circuits of the pulmonary-systemic vasculature before chance delivery in cardiac output to splanchnic arteries that lead indirectly to the portal tract. The kinetics of migration through different capillary beds was established, with the lungs of naïve mice not the skin proving the greatest obstacle; a proportion of schistosomula entered the alveoli from where they did not recover. The 'immunity' displayed by mice with a chronic infection was shown to be an artefact of a 'leaky' hepatic portal system, generated as a result of egg-induced hepatic pathology. The blockade of pulmonary migration was exacerbated in mice vaccinated with irradiated cercariae by immune-mediated inflammatory foci that developed around lung schistosomula thus decreasing the proportion that matured, but parasite elimination was a prolonged process, not an acute cytolytic 'hit.'

Entities:  

Mesh:

Year:  2009        PMID: 19265564     DOI: 10.1017/S0031182009005708

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  38 in total

1.  Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections.

Authors:  Mark S Wilson; Carl G Feng; Daniel L Barber; Felix Yarovinsky; Allen W Cheever; Alan Sher; Michael Grigg; Mary Collins; Lynette Fouser; Thomas A Wynn
Journal:  J Immunol       Date:  2010-03-10       Impact factor: 5.422

2.  Host mouse strain is not selective for a laboratory adapted strain of Schistosoma mansoni.

Authors:  Walter A Blank; Shi Fan Liu; Jayendra Prasad; Ronald E Blanton
Journal:  J Parasitol       Date:  2010-11-19       Impact factor: 1.276

Review 3.  Schistosomiasis-associated pulmonary hypertension.

Authors:  Demosthenes G Papamatheakis; Ana Olga H Mocumbi; Nick H Kim; Jess Mandel
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

4.  In vivo imaging of schistosomes to assess disease burden using positron emission tomography (PET).

Authors:  Nicolas Salem; Jason D Balkman; Jing Wang; David L Wilson; Zhenghong Lee; Christopher L King; James P Basilion
Journal:  PLoS Negl Trop Dis       Date:  2010-09-21

Review 5.  Immune effector mechanisms against schistosomiasis: looking for a chink in the parasite's armour.

Authors:  R Alan Wilson; Patricia S Coulson
Journal:  Trends Parasitol       Date:  2009-08-28

Review 6.  Advances in the Diagnosis of Human Schistosomiasis.

Authors:  Kosala G A D Weerakoon; Geoffrey N Gobert; Pengfei Cai; Donald P McManus
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

Review 7.  Structure-function analysis of apical membrane-associated molecules of the tegument of schistosome parasites of humans: prospects for identification of novel targets for parasite control.

Authors:  Chiuan Yee Leow; Charlene Willis; Andreas Hofmann; Malcolm K Jones
Journal:  Br J Pharmacol       Date:  2014-12-23       Impact factor: 8.739

Review 8.  The use of imaging to detect schistosomes and diagnose schistosomiasis.

Authors:  P J Skelly
Journal:  Parasite Immunol       Date:  2013 Sep-Oct       Impact factor: 2.280

Review 9.  Human schistosomiasis.

Authors:  Daniel G Colley; Amaya L Bustinduy; W Evan Secor; Charles H King
Journal:  Lancet       Date:  2014-04-01       Impact factor: 79.321

10.  Host-Specific Serum Factors Control the Development and Survival of Schistosoma mansoni.

Authors:  Sören Frahm; Ulrich Fabien Prodjinotho; Sonakshi Bhattacharjee; Admar Verschoor; Clarissa Prazeres da Costa
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.